Finance
Sanofi to Acquire Dren Bio's Immunology Unit
Published by Global Banking & Finance Review®
Posted on March 20, 2025
1 min readLast updated: January 24, 2026
Add as preferred source on GoogleGlobal Banking & Finance Review®
Company
Published by Global Banking & Finance Review®
Posted on March 20, 2025
1 min readLast updated: January 24, 2026
Add as preferred source on GoogleSanofi will acquire Dren Bio's autoimmune unit DR-0201 for $600M upfront, with potential future payments of $1.3B. The deal is set to close in Q2 2025.
(Reuters) - Sanofi on Thursday announced an agreement with biopharmaceutical company Dren Bio for the acquisition of its autoimmune disease treatment DR-0201.
The French healthcare group will acquire the Dren Bio affiliate Dren-0201 for an upfront payment of $600 million and potential future payments totalling $1.3 billion, it said in a statement.
The transaction is expected to close in the second quarter of 2025, it added.
(Reporting by Alban Kacher)
The main topic is Sanofi's acquisition of Dren Bio's autoimmune unit DR-0201 for $600 million upfront, with potential future payments totaling $1.3 billion.
The deal includes an upfront payment of $600 million, with potential future payments totaling $1.3 billion.
The transaction is expected to close in the second quarter of 2025.
Explore more articles in the Finance category
